Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.37 USD
0.00 (0.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.36 -0.01 (-0.73%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Spero Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 22.81 | -46.42 | -89.76 | -78.28 | -60.93 |
Depreciation/Amortization & Depletion | 0.37 | 0.87 | 0.65 | 0.76 | 0.75 |
Net Change from Assets/Liabilities | -70.37 | 22.09 | 12.86 | -13.46 | 6.78 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 14.21 | 15.73 | 11.90 | 5.11 | 3.38 |
Net Cash From Operating Activities | -33.00 | -7.73 | -64.35 | -85.87 | -50.02 |
Property & Equipment | 0.00 | 0.00 | 0.04 | -0.16 | -0.31 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 33.81 | 7.63 | 10.63 | 29.84 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 33.81 | 7.67 | 10.47 | 29.53 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.22 | 24.93 | 9.28 | 131.83 | 16.30 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -54.49 | 74.77 | -0.95 | -0.16 |
Net Cash from Financing Activities | 0.22 | -29.55 | 84.05 | 130.88 | 16.14 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -32.77 | -3.48 | 27.38 | 55.48 | -4.35 |
Cash at Beginning of Period | 109.11 | 112.58 | 85.21 | 29.73 | 34.08 |
Cash at End of Period | 76.33 | 109.11 | 112.58 | 85.21 | 29.73 |
Diluted Net EPS | 0.43 | -1.23 | -2.91 | -3.52 | -3.35 |
Fiscal Year End for Spero Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -30.53 | -12.67 | 22.81 | -28.39 | -25.18 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.37 | 0.33 | 0.22 |
Net Change from Assets/Liabilities | 13.08 | 16.33 | -70.37 | 0.59 | -10.96 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.65 | 2.28 | 14.21 | 11.96 | 4.50 |
Net Cash From Operating Activities | -12.81 | 5.94 | -33.00 | -15.50 | -31.42 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.00 | 0.22 | 0.22 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.00 | 0.00 | 0.22 | 0.22 | 0.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -12.81 | 5.94 | -32.77 | -15.28 | -31.42 |
Cash at Beginning of Period | 76.33 | 76.33 | 109.11 | 109.11 | 109.11 |
Cash at End of Period | 63.53 | 82.27 | 76.33 | 93.83 | 77.69 |
Diluted Net EPS | -0.33 | -0.24 | 0.97 | -0.06 | -0.23 |